JAK Inhibitor Dose TAPering Strategy Study
ConditionRhumatoid Arthisis
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity Hospital, Toulouse
About this trial
This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose.
Participants will:
* Either take
1. JAK inhibitor dose-tapering strategy. 2. JAK inhibitor continuous therapy strategy. * Visit the clinic once every 3 months for checkups and tests * Keep a diary of their treatment intake and symptoms
Eligibility criteria
Qualifiers
Aged ≥ 18 years at baseline.
Rheumatoid arthritis defined by the ACR/EULAR criteria.
Treated with a JAK inhibitor, full dose for at least 6 months.
The JAK inhibitor is prescribed as monotherapy or combined with a csDMARD with a stable dosage for at least 3 months before inclusion.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Baricitinib (LY3009104) 4 mg
- filgotinib 200mg/day
- Tofacitinib 5 mg twice daily
- Upadacitinib 15 MG
- Baricitinib (LY3009104) 4 mg
- filgotinib 200mg/day
- Tofacitinib 5 mg twice daily
- Upadacitinib 15 MG
Treatment groups
308 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov